Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Mult Scler. 2024 Sep;30(10):1370-1373. doi: 10.1177/13524585241260537. Epub 2024 Jun 16.
Cases of herpes zoster (HZ) in patients with MS on natalizumab (NTZ) have been documented. In this study, we assessed lymphocyte subsets in NTZ-treated patients with HZ compared to matched controls without HZ. Twenty unvaccinated patients developed HZ while on NTZ for an incidence rate of 12.3 per 1000 patient-years. These patients had lower CD8+% and higher CD4+:CD8+ ratios ( ⩽ 0.01) than non-HZ matched controls. Two patients with relapsing-remitting MS developed HZ twice while on NTZ. These findings underscore the importance of pre-NTZ HZ vaccination due to potential HZ risk.
已有报道称，在接受那他珠单抗（NTZ）治疗的多发性硬化症（MS）患者中出现了带状疱疹（HZ）病例。在这项研究中，我们评估了与未发生 HZ 的匹配对照组相比，在接受 NTZ 治疗的 HZ 患者中的淋巴细胞亚群。在接受 NTZ 治疗期间，有 20 名未接种疫苗的患者发生 HZ，HZ 发生率为每 1000 患者年 12.3 例。与未发生 HZ 的匹配对照组相比，这些患者的 CD8+%较低，CD4+:CD8+比值较高（ ⩽ 0.01）。两名复发性缓解型 MS 患者在接受 NTZ 治疗期间发生了两次 HZ。这些发现强调了在接受 NTZ 治疗前进行 HZ 疫苗接种的重要性，因为存在潜在的 HZ 风险。
